Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib dose-escalation study of ROSE12 alone and with immune checkpoint inhibitors in advanced solid tumors
jRCT2031230072Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of ROSE12 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of ROSE12, Anti-tumor activity of ROSE12 and 1 more. Started May 2023; status: recruiting.
02
Drugs
ROSE12
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031230072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230072.